Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
Revenue : Revenue was approximately zero for Q4 and $0.1 million for the full year 2023, following the termination of the GSK Agreement. R&D Expenses : R&D expenses increased to $47.0 million for Q4 and $182.9 million for the full year 2023. Cash Position : Ended the year with $562.7 million in cash, cash equivalents, and marketable securities. Clinical Trials : On track to report initial data from Phase 1 trials of lead CAR T-cell and TIL product candidates in 2024. Orphan Drug Designation : Received for LYL845 for the treatment of melanoma. IND Submission : Expect to submit IND for second-generation ROR1-targeted CAR T-cell product in the first half of 2024. Warning! GuruFocus has detected 2 Warning Signs with XPER. On February 28, 2024, Lyell Immunopharma Inc ( NASDAQ:LYEL ), a clinical-stage T-cell reprogramming company dedicated to the mastery of T cells to eradicate solid tumors, released its 8-K filing , detailing its financial results and business highlights for
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024GlobeNewswire
- Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]Seeking Alpha
- Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 2seventy bio appoints Eli Casdin and Charles Newton to its board of directors [Seeking Alpha]Seeking Alpha
LYEL
Sec Filings
- 5/6/24 - Form 424B5
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- LYEL's page on the SEC website